Peptide LexiconAll compounds

Plecanatide (Trulance): The 16-Amino-Acid Copy of a Gut Hormone, One Letter Changed

Plecanatide is a 16-amino-acid peptide sold as Trulance for chronic constipation and constipation-type irritable bowel syndrome in adults. It copies uroguanylin, a hormone the gut makes, with a single amino acid swapped. This entry covers the structure, how it works in the gut, the phase 3 trials and the label's paediatric warning.

Approved drug (US, 2017)Prescription onlyBoxed warning

Caroline S · Published 2026-11-16

Length

16 amino acids — C65H104N18O26S4, molecular weight 1,682 (Trulance label)

Sequence

NDECELCVNVACTGCL, disulfide bridges 4–12 and 7–15 (Trulance label, section 11)

Origin

Synthetic analogue of human uroguanylin (UniProt Q16661)

Last reviewed

2026-11-16

What is it good for?

Plecanatide is a prescription tablet approved in the United States for adults with chronic idiopathic constipation and with irritable bowel syndrome with constipation (IBS-C). In its constipation trial about one in five patients on the drug were durable responders over 12 weeks, against one in ten on placebo. It acts inside the gut and is barely absorbed.

Illustration: A molecular model of a short peptide chain in white and deep green, with one copper sphere.
Illustration

What it is

Plecanatide is a peptide of 16 amino acids that copies uroguanylin, a hormone the small intestine makes for itself. It is sold in the United States as Trulance, a 3 mg tablet, first approved on 19 January 2017 for chronic idiopathic constipation (Drugs@FDA, NDA 208745, sponsor Salix). The current label adds irritable bowel syndrome with constipation, both in adults.

The label gives the chain as NDECELCVNVACTGCL, folded by two sulfur-to-sulfur bridges between cysteines 4 and 12 and between 7 and 15 (Trulance label, section 11).

Property Value Source
Length 16 amino acids Trulance label
Sequence NDECELCVNVACTGCL Trulance label
Disulfide bridges Cys4–Cys12, Cys7–Cys15 Trulance label
Formula C65H104N18O26S4 Trulance label
Molecular weight 1,682 Da Trulance label
Natural template Uroguanylin, 16 residues, cut from a 112-residue precursor UniProt Q16661

One letter apart. UniProt's record for the human uroguanylin precursor (Q16661, read 2026-11-16) gives the mature hormone as NDDCELCVNVACTGCL. Set beside the label sequence, the two differ only at position 3 — aspartic acid (D) in the hormone, glutamic acid (E) in the drug (our comparison). The four sulfur atoms in the drug's formula match its four cysteines.

How it works

Plecanatide binds guanylate cyclase-C, a receptor on the cells lining the intestine. For the same receptor, the Linzess label describes the chain of events: a rise in cyclic GMP inside the cell opens the CFTR channel, chloride and bicarbonate pass into the gut, and water follows. The drug acts on the inside surface of the gut: in a single-dose study in 72 healthy volunteers given between 0.1 and 48.6 mg, the authors described it as acting locally in the gastrointestinal tract (Shailubhai et al. 2013, PMID 23625291).

The same receptor is the target of linaclotide, the other approved peptide in this class, 14 amino acids long with three disulfide bridges.

What the trials showed

Trial People Primary result over 12 weeks Source
Chronic idiopathic constipation, phase 3 1,394 Durable responders 21.0% (3 mg), 19.5% (6 mg), 10.2% placebo Miner 2017, PMID 28169285
IBS-C, study 1 part of 2,189 Overall responders 30.2% (3 mg), 29.5% (6 mg), 17.8% placebo Brenner 2018, PMID 29545635
IBS-C, study 2 part of 2,189 21.5% (3 mg), 24.0% (6 mg), 14.2% placebo Brenner 2018, PMID 29545635

In the constipation trial, complete spontaneous bowel movements rose by 2.5 a week on 3 mg against 1.2 on placebo. Diarrhoea was the most common adverse event: 5.9% on 3 mg, 5.7% on 6 mg, 1.3% on placebo.

What the numbers mean in plain terms: most people in every arm, drug or placebo, did not meet the responder definition. The drug roughly doubled the share who did. The trials ran 12 weeks; the 6 mg dose did no better than 3 mg, and the label lists only a 3 mg tablet.

Safety on the label

The Trulance label carries a boxed warning on serious dehydration in children. It is contraindicated under 6 years of age because, in nonclinical studies in young juvenile mice, a single oral dose caused deaths from dehydration. The label says to avoid it from 6 to under 18 and that safety and effectiveness have not been established under 18.

Where it stands

Plecanatide is a prescription drug with two adult indications in the United States. It is not a research peptide or a supplement, and no evidence in the record supports any other use. Questions about constipation treatment belong to a doctor; GLP1Ledger's constipation page covers the separate question of constipation on GLP-1 medicines.

Sources opened 2026-11-16: Trulance prescribing information (openFDA, revision 2024-04-04); Drugs@FDA NDA 208745; UniProt Q16661; Miner et al. 2017 (PMID 28169285); Brenner et al. 2018 (PMID 29545635); Shailubhai et al. 2013 (PMID 23625291); PubMed and ClinicalTrials.gov API v2 counts.

What the research shows

Improves chronic idiopathic constipation

Miner et al. 2017, Am J Gastroenterol (PMID 28169285): 1,394 patients, 12 weeks; durable overall responders 21.0% (3 mg) and 19.5% (6 mg) vs 10.2% placebo

Improves IBS with constipation

Brenner et al. 2018, Am J Gastroenterol (PMID 29545635): two identical phase 3 trials, 2,189 randomised; overall responders 30.2% / 29.5% vs 17.8% placebo (study 1) and 21.5% / 24.0% vs 14.2% (study 2)

Draws fluid into the gut by activating guanylate cyclase-C

Trulance label (GC-C agonist); Shailubhai et al. 2013 single-dose study in 72 healthy volunteers (PMID 23625291)

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Trulance, NDA 208745, Salix; original approval 2017-01-19 for chronic idiopathic constipation (Drugs@FDA). The current label lists both CIC and IBS-C in adults (openFDA revision 2024-04-04).

Form on the label

Tablets, 3 mg. Reported as the label states it, not as guidance.

Published record

PubMed: 136 records naming plecanatide, 11 tagged as randomised trials. ClinicalTrials.gov: 15 studies list it as an intervention (2026-11-16).

Frequently asked questions

What is plecanatide?

A 16-amino-acid peptide sold as Trulance tablets. It copies uroguanylin, a hormone made in the gut, and is approved in the United States for chronic idiopathic constipation and IBS with constipation in adults.

How does plecanatide work?

It switches on a receptor called guanylate cyclase-C on the cells lining the intestine. That releases fluid into the gut and softens stool. It acts locally and very little reaches the blood.

How is plecanatide different from uroguanylin?

By one amino acid. Comparing the Trulance label with UniProt's uroguanylin record, the third residue is glutamic acid in plecanatide and aspartic acid in the natural hormone; the other fifteen match.

How is plecanatide different from linaclotide?

Both are peptides that act on the same gut receptor. Linaclotide (Linzess) is 14 amino acids with three disulfide bridges; plecanatide is 16 amino acids with two bridges and copies a human gut hormone, uroguanylin.

Why does Trulance carry a warning for children?

In studies in young juvenile mice, a single oral dose caused deaths from dehydration. The label contraindicates it under 6, says to avoid it from 6 to under 18, and states safety is not established under 18.

What was the most common side effect in the trials?

Diarrhoea. In the constipation trial it occurred in 5.9% on 3 mg, 5.7% on 6 mg and 1.3% on placebo.